Second Sight Medical Products INC: insider trades · United States · SEC (Form 4)

About Second Sight Medical Products INC

Second Sight Medical Products Inc. was a U.S.-based medical technology company best known for pioneering implantable devices designed to restore a form of functional vision in patients with severe blindness. Founded in 1998 as Second Sight LLC and incorporated in California in 2003, the company built its identity around highly specialized neuroprosthetic solutions at the intersection of ophthalmology, neurology, and biomedical engineering. Historically, it was headquartered in Sylmar, California, in the Los Angeles area, and it also maintained a Swiss presence to support clinical and commercial activities outside the United States. At the time it was publicly traded on NASDAQ under the ticker EYES, Second Sight was one of the very few pure-play companies focused on “artificial vision.” Its flagship product was the Argus II retinal prosthesis, developed for patients suffering from outer retinal degenerations, especially retinitis pigmentosa. Argus II was a landmark device in the field because it became the first retinal prosthesis approved by the U.S. FDA. That regulatory achievement gave Second Sight a strong scientific profile and a meaningful first-mover advantage in a very narrow niche. The company’s competitive positioning was driven less by scale and more by technological barriers: advanced microelectronics, implantable hardware, software, signal processing, and the surgical know-how required to deliver vision-related neurostimulation. Geographically, the business was always relatively international for a small medtech company, with U.S. operations complemented by European clinical and commercial capabilities. In its SEC filings, Second Sight described a broader mission to develop prosthetic systems that could restore useful visual perception and, more generally, targeted neurostimulation technologies. For investors, however, the key point is that the original listed company no longer exists in its historical form. Second Sight was absorbed into a corporate restructuring process and changed identity in the merger with Nano Precision Medical, becoming part of what is now Vivani Medical. As a result, any analysis of Second Sight today is necessarily retrospective and should be framed as an assessment of its legacy technology and corporate history. Recent developments are therefore primarily corporate rather than operational: restructuring, a change in corporate direction, and the transition away from the original vision-prosthetics business model. From an analyst’s perspective, Second Sight is a useful case study in high-risk medtech innovation, highlighting the long development cycles, financing needs, and regulatory hurdles that define breakthrough medical device programs. In short, it was a pioneering U.S. medical device company, historically listed on NASDAQ in the United States, with a recognized scientific legacy but a corporate trajectory that has since been fundamentally reshaped.